Drug Search Results
More Filters [+]

Sevirumab

Alternative Names: sevirumab
Latest Update: 2012-10-25
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: N/A

Novel Mechanism: No

Modality: Antibody

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Sandoz
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Sevirumab

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: HIV Infections|Cytomegalovirus Infections|Cytomegalovirus Retinitis

Phase 1: HIV Infections|Cytomegalovirus Retinitis|Acquired Immunodeficiency Syndrome|Communicable Diseases|Cytomegalovirus Infections|Deficiency Diseases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

071B

P1

Completed

HIV Infections|Cytomegalovirus Retinitis|Cytomegalovirus Infections|Acquired Immunodeficiency Syndrome

None

MACRT

P2

Completed

HIV Infections|Cytomegalovirus Infections|Cytomegalovirus Retinitis

None

071A

P1

Completed

Acquired Immunodeficiency Syndrome|Communicable Diseases|HIV Infections|Deficiency Diseases|Cytomegalovirus Infections

None

Recent News Events

Date

Type

Title